Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-lipiodol emulsion

CardioVascular and Interventional Radiology

Volumn 35, Issue 1, 2012, Pages 82-89

  Maeda, Noboru ^a   Osuga, Keigo ^a   Higashihara, Hiroki ^a   Tomoda, Kaname ^a   Mikami, Koji ^b   Nakazawa, Tetsuro ^c   Nakamura, Hironobu ^d   Tomiyama, Noriyuki ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Suita Municipal Hospital   (Japan)

^c NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^d Saito Yukoukai Hospital   (Japan)

Author keywords

Cisplatin; Epirubicin; Hepatocellular carcinoma; Second line treatment; Transarterial chemoembolization

Indexed keywords

CISPLATIN; EPIRUBICIN; IODINATED POPPYSEED OIL;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILOMA; BLOOD TOXICITY; CHEMOEMBOLIZATION; CHILL; CHOLECYSTITIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; CISPLATIN; DISEASE PROGRESSION; EMULSIONS; EPIRUBICIN; ETHIODIZED OIL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84857036979     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-010-0086-6     Document Type: Article

References (20)

1. FX Bosch J Ribes M Diaz, et al. 2004 Primary liver cancer: worldwide incidence and trends Gastroenterology 127 5 Suppl 1 S5 S16 15508102 10.1053/j.gastro.2004.09.011 (Pubitemid 39423365)
2. JM Llovet J Bruix 2003 Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival Hepatology 37 2 429 442 12540794 10.1053/jhep.2003.50047 1:CAS:528: DC%2BD3sXhsFeltrg%3D (Pubitemid 36152543)
3. JM Llovet MI Real X Montana, et al. 2002 Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 9319 1734 1739 12049862 10.1016/S0140-6736(02)08649-X (Pubitemid 34607087)
4. C Cammà F Schepis A Orlando, et al. 2002 Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials Radiology 224 1 47 54 12091661 10.1148/radiol. 2241011262 (Pubitemid 34680374)
5. Brown DB, Cardella JF, Sacks D et al (2009) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 20(7 Suppl):S219-S226, S226.e1-10
6. Y Kawamura K Ikeda M Hirakawa, et al. 2009 Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin Hepatol Res 39 4 346 354 19054145 10.1111/j.1872-034X.2008.00466.x 1:CAS:528:DC%2BD1MXovVCitbg%3D
7. A Seki T Igarashi T Kawauchi, et al. 2009 Transcatheter arterial chemoembolization with cisplatin-Lipiodol emulsion for epirubicin-Lipiodol TACE resistant unresectable hepatocellular carcinoma: Initial evaluation of efficacy and toxicity [in Japanese] Jpn J Intervent Radiol 24 3 252 257
8. M Yoshikawa N Ono H Yodono, et al. 2008 Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma Hepatol Res 38 5 474 483 18430093 10.1111/j.1872-034X. 2008.00338.x 1:CAS:528:DC%2BD1cXptlajsLw%3D (Pubitemid 351593948)
9. N Maeda K Osuga H Higashihara, et al. 2010 In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization J Vasc Interv Radiol 21 6 877 881 20417118 10.1016/j.jvir.2010.02.009
10. Y Takaki T Kaminou M Shabana, et al. 2008 Suitable blending method of lipiodol-cisplatin in transcatheter arterial embolization for hepatocellular carcinoma: evaluation of sustained release and accumulation nature Hepatogastroenterology 55 81 202 206 18507107 1:CAS:528:DC%2BD1cXkslOgsrY%3D (Pubitemid 351462191)
11. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10655437 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
12. J Bruix M Sherman JM Llovet, et al. 2001 Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 3 21 30 10.1016/S0168-8278(01)00130-1 (Pubitemid 32844200)
13. JM Llovet M Beaugrand 2003 Hepatocellular carcinoma: present status and future prospects J Hepatol 38 Suppl 1 S136 S149 12591191 10.1016/S0168-8278(02) 00432-4 (Pubitemid 39658641)
14. A Trotti D Colevas A Setser, et al. 2003 CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 13 176 781 12903007 10.1016/S1053-4296(03)00031-6 (Pubitemid 36962641)
15. CM Lo H Ngan WK Tso, et al. 2002 Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 5 1164 1171 11981766 10.1053/jhep.2002.33156 1:CAS:528:DC%2BD38XktF2hu7w%3D (Pubitemid 34454013)
16. DW Shen S Akiyama P Schoenlein, et al. 1995 Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes Br J Cancer 71 4 676 683 7710928 10.1038/bjc.1995.134 1:CAS:528:DyaK2MXmtF2ksLw%3D
17. Ono Y, Yoshimasu T, Ashikaga R et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinoma. Am J Clin Oncol 23(6):564-548
18. T Kawaoka H Aikata S Takaki, et al. 2009 Transarterial infusion chemotherapy using cisplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma Cardiovasc Intervent Radiol 32 4 687 694 19444503 10.1007/s00270-009-9570-2
19. K Morimoto H Sakaguchi T Tanaka, et al. 2008 Transarterial chemoembolization using cisplatin powder in a rabbit model of liver cancer Cardiovasc Intervent Radiol 31 5 981 985 18535857 10.1007/s00270-008-9367-8
20. K Lu YH Li XF He, et al. 2008 Necrosis and apoptosis in hepatocellular carcinoma following low-dose versus high-dose preoperative chemoembolization Cardiovasc Intervent Radiol 31 6 1133 1140 18584240 10.1007/s00270-008-9379-4